Top

Published in:

01-01-2016 | Review Article

Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses

Authors: Yuehong Chen, Jianhong Sun, Yuan Yang, Yupeng Huang, Gang Liu

Published in: Clinical Rheumatology | Issue 1/2016

Abstract

The objective of the study is to systematically review the malignancy risk of anti-tumor necrosis factor alpha (anti-TNFα) agents. Databases of PubMed Medline, OVID EMBASE, and Cochrane Library were searched to identify published systematic reviews and meta-analyses of randomized control trials, observational studies, and case series that evaluated malignancy risk of anti-TNFα blockers. Search time duration was restricted from January 1st, 2000 to July 16th, 2015. Overview Quality Assessment Questionnaires were used to assess the quality of included reviews. Two methodology trained reviewers separately and repeatedly screened searched studies according to study selection criteria, collected data, and assessed quality. Totally, 42 reviews proved eligible with only one Cochrane review. Anti-TNFα antagonists were extensively used to treat various diseases; nevertheless, malignancy risks were most commonly described in patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). In RA patients, no increased risks of breast cancer, lymphoma, and non-melanoma skin cancer were found, but if the use of anti-TNFα agents was associated with elevated risk of overall malignancy was still uncertainty. In IBD patients, the use of anti-TNFα inhibitors was not connected with enhanced risk of overall cancer. No increased cancer risk was found in other disease conditions. Twenty-nine reviews were rated as good quality, 12 as moderate, and one as poor. There are no sufficient evidences to draw the conclusion that anti-TNFα blockers have relationship with increased malignancy risk.

Available only for authorised users

Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL (2003) Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2(9):736–46PubMedCrossRef

Zelova H, Hosek J (2013) TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm Res 62(7):641–51PubMedCrossRef

Nanau RM, Neuman MG (2014) Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 17(3):324–61PubMed

Damjanov N, Nurmohamed MT, Szekanecz Z (2014) Biologics, cardiovascular effects and cancer. BMC Med 12:48PubMedPubMedCentralCrossRef

Jain A, Singh JA (2013) Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy 5(3):265–99PubMedPubMedCentralCrossRef

Liu Y, Fan W, Chen H, Yu MX (2014) Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials. Asian Pac J Cancer Prev 15(8):3403–10PubMedCrossRef

Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK (2014) The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 127(12):1208–32PubMedCrossRef

Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B (2012) Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 30(5):756–64PubMed

Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR et al (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898–908PubMedCrossRef

10.

Moulis G, Sommet A, Bene J, Montastruc F, Sailler L, Montastruc JL et al (2012) Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One 7(11):e48991PubMedPubMedCentralCrossRef

11.

Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B (2012) Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol 39(4):712–5CrossRef

12.

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–85PubMedCrossRef

13.

Higgins JPT and Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chapter 1: Introduction, systematic reviews. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org

14.

Oxman AD, Guyatt GH (1991) Validation of an index of the quality of review articles. J Clin Epidemiol 44(11):1271–8PubMedCrossRef

15.

Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol 37(6):1096–104PubMedCrossRef

16.

Song Y-N, Zheng P (2015) Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: a systematic review and meta-analysis of published randomized controlled trials. J Food Drug Anal 23(1):1–10CrossRef

17.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA (2014) Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 12(9):1443–51, quiz e88-9PubMedCrossRef

18.

Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E (2014) The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One 9(12):e115026PubMedPubMedCentralCrossRef

19.

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L et al (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):529–35PubMedCrossRef

20.

Silva-Fernandez L, Loza E, Martinez-Taboada VM, Blanco R, Rua-Figueroa I, Pego-Reigosa JM et al (2014) Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum 43(4):542–57PubMedCrossRef

21.

Song YN, Zheng P, Xiao JH, Lu ZJ (2014) Efficacy and safety of adalimumab for the Crohn’s disease: a systematic review and meta-analysis of published randomized placebo-controlled trials. Eur J Clin Pharmacol 70(8):907–14PubMedCrossRef

22.

Williams CJ, Peyrin-Biroulet L, Ford AC (2014) Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 39(5):447–58PubMedCrossRef

23.

Blok JL, van Hattem S, Jonkman MF, Horvath B (2013) Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 168(2):243–52PubMedCrossRef

24.

Li ZH, Zhang Y, Wang J, Shi ZJ (2013) Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol 23(5):497–506PubMedCrossRef

25.

Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM (2013) The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum 42(6):597–618PubMedCrossRef

26.

Zhang D, Xiong B, Li X, Xu T, Yu M (2013) Meta-analysis: serious adverse events in Crohn’s disease patients treated with TNF-alpha inhibitors. Hepatogastroenterology 60(126):1333–42PubMed

27.

Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L (2012) Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin Arthritis Rheum 42(1):89–103PubMedCrossRef

28.

Solomon DH, Mercer E, Kavanaugh A (2012) Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 64(1):21–32PubMedPubMedCentralCrossRef

29.

Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST (2012) Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 31(4):631–6PubMedCrossRef

30.

Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119–30PubMedCrossRef

31.

Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64(6):1035–50PubMedPubMedCentralCrossRef

32.

Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD (2011) Efficacy and safety of adalimumab in Crohn’s disease: meta-analysis of placebo-controlled trials. J Dig Dis 12(3):165–72PubMedCrossRef

33.

Huang X, Lv B, Jin HF, Zhang S (2011) A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. Eur J Clin Pharmacol 67(8):759–66PubMedCrossRef

34.

Lin Z, Bai Y, Zheng P (2011) Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease. Eur J Gastroenterol Hepatol 23(12):1100–10PubMedCrossRef

35.

Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–904PubMedCrossRef

36.

Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479–85PubMedCrossRef

37.

Zidi I, Bouaziz A, Mnif W, Bartegi A, Ben AN (2011) Golimumab and malignancies: true or false association? Med Oncol 28(2):641–8PubMedCrossRef

38.

Ma MHY, Cope AP, Scott DL (2010) Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate. Int J Clin Rheumatol 5(5):547–554CrossRef

39.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976–86PubMedCrossRef

40.

Oussalah A, Danese S, Peyrin-Biroulet L (2010) Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 11(2):156–75PubMedCrossRef

41.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R (2010) Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30(4):339–53PubMedCrossRef

42.

Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177–83PubMedCrossRef

43.

Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136–45PubMedCrossRef

44.

Nannini C, Cantini F, Niccoli L, Cassara E, Salvarani C, Olivieri I et al (2009) Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61(6):801–12PubMedCrossRef

45.

Shao LM, Chen MY, Cai JT (2009) Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease. Aliment Pharmacol Ther 29(6):605–14PubMedCrossRef

46.

Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE (2009) Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 7(8):874–81PubMedPubMedCentralCrossRef

47.

Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A (2008) Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159(2):274–85PubMedCrossRef

48.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6(6):644–53PubMedCrossRef

49.

Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33(12):2398–408PubMed

50.

Costenbader KH, Glass R, Cui J, Shadick N (2006) Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296(18):2201, author reply 2203–4PubMedCrossRef

51.

de Chambrun GP, Peyrin-Biroulet L, Vroey BD, Colombel JF (2011) Lymphoma and IBD: what is the actual risk? Inflamm Bowel Dis Monit 11(3):93–102

52.

Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64(5):699–703PubMedPubMedCentralCrossRef

53.

Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740–51PubMedCrossRef

54.

Kaiser R (2008) Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 8(2):87–93PubMedCrossRef

55.

Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111(8):4029–38PubMedPubMedCentralCrossRef

56.

Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886–95PubMedCrossRef

57.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–39CrossRef

58.

Pierard-Franchimont C, Pierard GE, Quatresooz P (2011) Focus on skin cancer association and progression under TNF antagonist therapy. Expert Opin Biol Ther 11(9):1215–22PubMedCrossRef

59.

Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50(1):196–203CrossRef

60.

Okada SK, Siegel JN (2006) Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296(18):2201–2, author reply 2203–4PubMedCrossRef

61.

Kamangar F, Neuhaus IM, Koo JY (2012) An evidence-based review of skin cancer rates on biologic therapies. J Dermatolog Treat 23(4):305–15PubMedCrossRef

62.

Remicade (infliximab) for IV injection. Prescribing information. Warnings and precautions (see Boxed WARNINGS) (5.2 malignancies) Malvern: Centocor; 2000. Avaible from http://www.fda.gov/safety/medwatch/safetyinformation/ucm194136.htm

63.

Codreanu C, Damjanov N (2015) Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics 9:1–6PubMedPubMedCentral

Title: Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses
Authors: Yuehong Chen
Jianhong Sun
Yuan Yang
Yupeng Huang
Gang Liu
Publication date: 01-01-2016
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 1/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-015-3115-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Enhancing the care of women with rheumatic diseases during pregnancy: challenges and unmet needs in the Middle East

Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis: a randomized controlled non-inferiority trial

The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels

Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease

Development of de novo major involvement during follow-up in Behçet’s syndrome

Deoxyribonuclease I gene polymorphism and susceptibility to systemic lupus erythematosus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials